FindTrial
Sign In

Humira®

DRUG8 trials

Sponsors

Fujifilm Kyowa Kirin Biologics Co., Ltd., Fresenius Kabi SwissBioSim GmbH, LG Life Sciences, Biocad, Boehringer Ingelheim

Conditions

Arthritis, RheumatoidCrohn's DiseaseHealthy ParticipantsIBDModerate to Severe Plaque PsoriasisPlaque Type PsoriasisPsoriasis

Phase 1

A Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants Under Fasting Conditions
CompletedNCT07147257
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.Healthy Participants
Start: 2025-02-12End: 2025-05-29Updated: 2026-01-28

Phase 2

An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease
TerminatedNCT03759288
AstraZenecaCrohn's Disease, IBD
Start: 2018-12-07End: 2023-10-18Updated: 2023-11-21

Phase 3

A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients
CompletedNCT02260791
Fujifilm Kyowa Kirin Biologics Co., Ltd.Arthritis, Rheumatoid
Start: 2014-12-31End: 2016-07-31Updated: 2017-11-28
A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients
CompletedNCT02405780
Fujifilm Kyowa Kirin Biologics Co., Ltd.Arthritis, Rheumatoid
Start: 2015-06-10End: 2018-01-18Updated: 2019-03-26
MSB11022 in Moderate to Severe Chronic Plaque Psoriasis
CompletedNCT02660580
Fresenius Kabi SwissBioSim GmbHModerate to Severe Plaque Psoriasis, Plaque Type Psoriasis, Psoriasis
Start: 2016-02-16End: 2017-12-18Updated: 2023-12-27
A Study Comparing LBAL to Humira® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
CompletedNCT02746380
LG Life SciencesArthritis, Rheumatoid
Start: 2016-04-13End: 2018-02-23Updated: 2021-03-15
Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira® in Patients With Moderate to Severe Plaque Psoriasis
CompletedNCT02762955
BiocadPsoriasis
Start: 2016-12-31End: 2018-10-15Updated: 2021-09-08
The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis
CompletedNCT03210259
Boehringer IngelheimPsoriasis
Start: 2017-07-10End: 2019-04-16Updated: 2021-07-14

Related Papers

Summary of Research: Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial.
2023-10-24
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial.
2022-08-0722 citations
Long-term data on the proposed adalimumab biosimilar BCD-057 in patients with moderate to severe psoriasis: A randomized controlled trial
PLoS ONE2022-02-076 citations
Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity.
2020-12-0134 citations
Antibodies to watch in 2020.
2020-01-01328 citations
FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension.
2019-12-1238 citations
Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study
Annals of the Rheumatic Diseases2018-03-07112 citations